Bristol Myers has change of heart on cardiovascular gene therapy pact, terminating uniQure deal

Bristol Myers Squibb is breaking off its collaboration and license agreement with uniQure, calling time on a pact that was intended to deliver gene therapies against multiple cardiovascular disease targets.